Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS

You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.

Click here to find out that this 8,788% cryptocurrency is.

Kurt Emster Biography and Net Worth

Director of CRISPR Therapeutics

Kurt Von Emster is a managing partner at Abingworth, a leading life science investment firm focused on therapeutics. He has been with the firm since 2015.

Von Emster serves or has served on the boards of numerous biotech and pharmaceutical companies, including Tizona Therapeutics, Vera Therapeutics, Trishula Therapeutics, Orbus Therapeutics, SFJ Pharmaceuticals, SutroVax, CymaBay, CRISPR Therapeutics, Kesios Therapeutics, Cytos Biotechnology, Aurinia Pharmaceutical, Somaxon Pharmaceuticals, and Facet Biotech.

Additionally, he was a founding partner of investment advisory firm venBIO LLC (2009 to 2015), a general partner and portfolio manager at MPM Capital (2000 to 2009), and the vice president of portfolio manager at Franklin Templeton Investments (1989 to 2000).

His investing career was launched at Franklin Templeton where he founded and managed several health and biotech funds in the 1990s, each earning 5-star rankings from Mornignstar. By 2000, he was managing over $2 billion in funds for the firm.

Von Emster earned his B.S. in business and economics from the University of California, Santa Barbara.

What is Kurt Von Emster's net worth?: The estimated net worth of Kurt Von Emster is at least $4.88 million as of September 29th, 2023. Mr. Emster owns 90,000 shares of CRISPR Therapeutics stock worth more than $4,879,800 as of April 26th. This net worth approximation does not reflect any other assets that Mr. Emster may own. Learn More about Kurt Von Emster's net worth.
How do I contact Kurt Von Emster?: The corporate mailing address for Mr. Emster and other CRISPR Therapeutics executives is BAARERSTRASSE 14, ZUG V8, CH-6300. CRISPR Therapeutics can also be reached via phone at (141) 561-3277 and via email at [email protected]. Learn More on Kurt Von Emster's contact information.
Has Kurt Von Emster been buying or selling shares of CRISPR Therapeutics?: Kurt Von Emster has not been actively trading shares of CRISPR Therapeutics during the past quarter. Most recently, Kurt Von Emster sold 72,934 shares of the business's stock in a transaction on Tuesday, December 18th. The shares were sold at an average price of $29.85, for a transaction totalling $2,177,079.90. Learn More on Kurt Von Emster's trading history.
Who are CRISPR Therapeutics' active insiders?: CRISPR Therapeutics' insider roster includes Bradley Bolzon (Director), Kurt Emster (Director), Tony Ho (VP), James Kasinger (General Counsel), Lawrence Klein (COO), Samarth Kulkarni (CEO), Rodger Novak (President), and Michael Tomsicek (CFO). Learn More on CRISPR Therapeutics' active insiders.
Are insiders buying or selling shares of CRISPR Therapeutics?: In the last year, insiders at the sold shares 11 times. They sold a total of 178,992 shares worth more than $12,029,834.57. The most recent insider tranaction occured on April, 15th when CEO Samarth Kulkarni sold 19,582 shares worth more than $1,173,157.62. Insiders at CRISPR Therapeutics own 4.1% of the company. Learn More about insider trades at CRISPR Therapeutics.
Information on this page was last updated on 4/15/2024.

Kurt Von Emster Insider Trading History at CRISPR Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/18/2018	Sell	72,934	$29.85	$2,177,079.90
6/5/2018	Sell	920	$12.51	$11,509.20	90,000
5/14/2018	Sell	650,000	$54.39	$35,353,500.00	5,629
5/11/2018	Sell	250,000	$52.84	$13,210,000.00
1/5/2018	Sell	92,337	$26.96	$2,489,405.52
1/2/2018	Sell	37,754	$26.76	$1,010,297.04
8/28/2017	Sell	88,011	$19.79	$1,741,737.69
8/25/2017	Sell	22,781	$19.42	$442,407.02
8/23/2017	Sell	17,989	$18.53	$333,336.17
8/21/2017	Sell	3,150	$18.52	$58,338.00
8/17/2017	Sell	34,141	$19.06	$650,727.46
8/15/2017	Sell	55,569	$19.59	$1,088,596.71
8/8/2017	Sell	35,473	$18.63	$660,861.99
8/4/2017	Sell	50,477	$17.81	$898,995.37
8/1/2017	Sell	5,512	$17.51	$96,515.12
7/28/2017	Sell	41,312	$17.63	$728,330.56
7/26/2017	Sell	32,930	$17.60	$579,568.00
7/14/2017	Sell	69,859	$16.84	$1,176,425.56
7/12/2017	Sell	31,992	$16.56	$529,787.52
7/5/2017	Sell	4,254	$16.26	$69,170.04
6/29/2017	Sell	43,202	$16.90	$730,113.80
6/27/2017	Sell	81,435	$17.08	$1,390,909.80
6/23/2017	Sell	32,368	$16.23	$525,332.64

Kurt Von Emster Buying and Selling Activity at CRISPR Therapeutics

CRISPR Therapeutics Company Overview

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

Today's Range

Now: $54.22

$52.81

$54.94

50 Day Range

MA: $71.13

$53.73

$89.12

2 Week Range

Now: $54.22

$37.55

$91.10

Volume

827,432 shs

Average Volume

1,795,094 shs

Market Capitalization

$4.60 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.76